---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-303162"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:54:54.685652+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences appoints Bhavesh Ashar as COO; Bensen becomes Chief Discovery Officer

## Summary
- Bhavesh Ashar appointed COO effective Dec 1, 2025; Daniel Bensen moved to Chief Discovery Officer.
- Ashar base salary $550,000; target annual incentive 40% of base.
- Granted options to purchase 300,000 shares vesting over 4 years (25% cliff at 1 year).
- Severance provisions: 12 months salary plus target bonus if terminated without cause outside change in control.
- Ashar previously Chief Commercial Officer at SpringWorks Therapeutics (Merck KGaA).

## SEC filing metadata
- accession: 0001193125-25-303162
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312525303162/0001193125-25-303162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312525303162/d57660d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-303162
- JSON: https://secwatch.observer/filing/0001193125-25-303162.json
- Plain text: https://secwatch.observer/filing/0001193125-25-303162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.